MOMENT study of METex14 NSCLC patients
Part of Cancer clinical trials.
This registry study enrolls people with advanced non-small cell lung cancer (NSCLC) that has a specific genetic change called METex14 skipping. It aims to learn about how these cancers are treated in real life, which may help future care decisions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign the informed consent form (ICF) to join
- You have advanced NSCLC in stages IIIB, IIIC, or IV
- Your tumor test must confirm a METex14 skipping change using an approved lab test
- You are starting or already receiving medicines that treat cancer throughout the body (systemic therapy)
- You cannot be enrolled in another clinical trial at the same time
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how different treatments work for people with advanced lung cancer that has a MET mutation. It aims to understand real-world treatment patterns and outcomes to help guide future care.
This trial tests REGN5093, a study drug, in adults with advanced lung cancer that has a specific change called a MET alteration. If you have this MET change, the study aims to see how well the drug controls the cancer and how safe it is.
This trial tests how well glumetinib works for non-small cell lung cancer (NSCLC) that has specific “MET” gene changes. It also checks safety and side effects, especially in people who can’t have surgery or have already had other treatments.
This trial tests a targeted drug for advanced non-small cell lung cancer that has a specific genetic change called MET exon 14 skipping. It aims to see if the drug can shrink tumors or slow the cancer's growth, and may help people who have or haven't had prior treatment.
This study compares crizotinib to standard chemotherapy for people with advanced (spread) non-small cell lung cancer that has a specific change called MET exon 14 skipping. The goal is to see which treatment works better and how safely it controls the cancer.
This trial tests a new drug called SKB571 for people with advanced lung cancer that has a specific change in the MET gene. The goal is to see if the drug can shrink tumors or stop them from growing.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.